Insulin-Sensitizing Agents –Thiazolidinediones (Glitazones)
- 1 January 2002
- journal article
- review article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 18 (sup1) , s31-s39
- https://doi.org/10.1185/030079902125000219
Abstract
Insulin resistance is a fundamental feature of type 2 diabetes and is also associated with increased cardiovascular risk. The thiazolidinediones are insulin sensitizing agents which improve insulin resistance by combining with an intranuclear hormone receptor. They have been shown in human studies to both reduce insulin resistance and improve pancreaticb-cell function. They are effective both as monotherapy and in combination with sulphonylureas or metformin in improving glycaemia, with evidence of improvement in other features of metabolic syndrome. They are generally well tolerated, do not cause hypoglycaemia and have the potential to provide sustained diabetic control and reduce cardiovascular risk. They appear to be an important advance in diabetes management but further work is still required to determine their true potential.Keywords
This publication has 13 references indexed in Scilit:
- Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.Diabetes Care, 2000
- Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes MellitusJAMA, 2000
- Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patientsDiabetic Medicine, 2000
- Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve‐week, randomized, placebo‐controlled studyDiabetes, Obesity and Metabolism, 1999
- Thiazolidinediones: a new class of antidiabetic drugsDiabetic Medicine, 1999
- RosiglitazoneDrugs, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: Current status and therapeutic possibilitiesPublished by Springer Nature ,1998
- The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010Diabetic Medicine, 1997
- Banting lecture 1988. Role of insulin resistance in human diseaseDiabetes, 1988